Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition

Histopathology

Volumn 42, Issue 6, 2003, Pages 530-540

  Colpaert, Cecile G ^a   Vermeulen, P B ^a   Van Beest, P ^a   Soubry, A ^c   Goovaerts, G ^b   Dirix, L Y ^b   Harris, A L ^d   Van Marck, E A ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Angiogenesis Group   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Breast cancer; Fibrin; Growth patterns; Hypoxia; Skin metastasis

Indexed keywords

CARBONATE DEHYDRATASE; FIBRIN; UVOMORULIN;

ANGIOGENESIS; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST LOBULAR CARCINOMA; CANCER GROWTH; CANCER INFILTRATION; CAPILLARY DENSITY; CELL PROLIFERATION; ENDOTHELIUM CELL; FIBRIN DEPOSITION; HUMAN; HUMAN TISSUE; HYPOXIA; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROSIS; SKIN METASTASIS; SKIN NECROSIS;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CADHERINS; CARBONIC ANHYDRASES; CELL HYPOXIA; FEMALE; FIBRIN; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; MICROCIRCULATION; NECROSIS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; SKIN; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0038509263     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2003.01629.x     Document Type: Article

References (46)

1. De Vita VT, Hellman S, Rosenberg SA eds. Cancer: principles and practice of oncology. 4th edn. Philadelphia: Lippincott Co., 1993: 1592.
2. Folkman J. Tumour angiogenesis: therapeutic implication. N. Engl. J. Med. 1971: 285; 1182-1186.
3. Folkman J. What is the evidence that tumours are angiogenesis dependent? J. Natl Cancer Inst. 1990: 82; 4-6.
4. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1995: 1; 149-153.
5. Pezzella F, Pastorino U, Tagliabue E et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am. J. Pathol. 1997; 151; 1417-1423.
6. Holash J, Maisonpierre PC, Compton D et al. Vessel cooption. regression and growth in tumors mediated by angiopoietins and VEGF. Science 1999: 284; 1994-1998.
7. Maniotis AJ, Folberg R, Hess A et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 1999: 155; 739-752.
8. Folberg R, Hendrix MJC, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 2000; 156; 361-381.
9. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl Acad. Sci. 2000; 97; 14608-14613.
10. Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularisation. Circ. Res. 1999; 85; 221-228.
11. Vermeulen PB, Colpaert C, Salgado R et al. Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J. Pathol. 2001: 195; 336-342.
12. Hasebe T, Tsuda H, Hirohashi S et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res. Treat. 1998; 49; 195-208.
13. Colpaert C, Vermeulen P, van Beest P et al. Intratumoural hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph-node negative breast cancer patients. Histopathology 2001; 39; 416-425.
14. Wykoff CC, Beasley NJ, Watson PH et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am. J. Pathol. 2001: 158; 1011-1019.
15. Chia SK, Wykoff CC, Watson PH et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J. Clin. Oncol. 2001; 19; 3660-3668.
16. Chalkley HW. Method for the quantitative morphologic analysis of tissues. J. Natl Cancer Inst. 1943: 4; 47-53.
17. Vermeulen PB, Gasparini G, Fox SB et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer 1996; 32A; 2474-2484.
18. Vermeulen PB, Gasparini G, Fox SB et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur. J. Cancer 2002: 38; 1564-1579.
19. Wykoff CC, Beasley NJ, Watson PH et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000; 60; 7075-7083.
20. Pezzella F, Di Bacco A, Andreola S, Nicholson AG, Pastorino U, Harris AL. Angiogenesis in primary lung cancer and lung secondaries. Eur. J. Cancer 1996; 32A; 2494-2500.
21. Folkman J. What is the evidence that tumors are angiogenesis dependent. J. Natl Cancer Inst. 1990; 82; 4-6.
22. Colpaert C, Vermeulen P, Jeuris W et al. Early distant relapse in 'node negative' breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. J. Pathol. 2001: 193; 442-449.
23. Jitsuiki Y, Hasebe T, Tsuda H et al. Optimizing microvessel counts according to tumor zone in invasive ductal carcinoma of the breast. Mod. Pathol. 1999: 12; 492-498.
24. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur. J. Cancer 2000: 36; 1649-1660.
25. Carmeliet P, Dor Y, Herbert JM et al. Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998: 394; 485-490.
26. Forsythe JA, Jiang BH, Iyer NV et al. Activation of vascular endothelial growth factor gene-transcription by hypoxia-inducible factor-1. Mol. Cell Biol. 1996; 16; 4604-4613.
27. Jiang BH, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 1997; 57; 5328-5335.
28. Maxwell PH, Dachs GU, Gleadle JM et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl Acad. Sci. USA 1997: 94; 8104-8109.
29. Salven P, Perhoniemi V, Tykka H, Maenpaa H, Joensuu H. Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res. Treat. 1999; 53; 161-166.
30. Berx G. Cleton-Jansen AM, Nollet F et al. E-cadherin is a tumour invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 1995: 14; 6107-6115.
31. Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int. J. Cancer 2001; 92; 404-408.
32. Zucker S, Mirza H, Conner CE et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int. J. Cancer 1998; 75; 780-786.
33. Yan SF, Lu J, Zou YS et al. Hypoxia-associated induction of early growth response-1 gene expression. J. Biol. Chem. 1999: 274; 15030-15040.
34. Folkman J. Tumor angiogenesis and tissue factor. Nature Med. 1996; 2; 167-168.
35. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am. J. Pathol. 1995: 146; 1029-1039.
36. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986: 315; 1650-1659.
37. Dumonde DC, Glynn LE. The reaction of guinea pigs to autologous and heterologous fibrin implants. J. Pathol. Bacteriol. 1965; 90; 649-657.
38. Shoji M, Hancock WW, Abe K et al. Activation of coagulation and angiogenesis in cancer. Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am. J. Pathol. 1998; 152; 399-362.
39. Vartanian RK, Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am. J. Pathol. 1994: 144; 1188-1194.
40. Fox S, Gatter KC, Bicknell R. et al. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res. 1993; 53; 4161-4163.
41. Vermeulen PB, Verhoeven D, Hubens G et al. Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. Ann. Oncol. 1995: 6; 59-64.
42. Vermeulen PB, Dirix LY, Libura J, Vanhoolst IF, Van Marck E. Van Oosterom AT. Correlation of the fractions of proliferating tumor and endothelial cells in breast and colorectal adenocarcinoma is independent of tumor histiotype and microvessel density. Microvascular Res. 1997: 54; 88-92.
43. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustín HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000; 60; 1388-1393.
44. Darland DC, D'Amore PA. Blood vessel maturation: vascular development comes of age. J. Clin. Invest. 1999: 103; 157-158.
45. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nature Med. 2000; 6; 389-395.
46. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 1999: 103; 159-165.